Earnings summaries and quarterly performance for Entrada Therapeutics.
Executive leadership at Entrada Therapeutics.
Board of directors at Entrada Therapeutics.
Research analysts covering Entrada Therapeutics.
Recent press releases and 8-K filings for TRDA.
Entrada Therapeutics Highlights 2026 Clinical Milestones and Ocular Pipeline Expansion
TRDA
Guidance Update
New Projects/Investments
- Entrada Therapeutics anticipates several value-driving catalysts in 2026, including top-line data from the first cohort of its ENTR-601-44 program in Q2 2026, first cohort data for ENTR-601-45 in mid-2026, and the completion of enrollment and dosing for the VX-670 program (partnered with Vertex) also in mid-2026.
- The company is expanding its focus into ocular diseases, having nominated ENTR-801 as its first clinical candidate for Usher syndrome type 2A, with plans to announce another clinical candidate in 2026.
- Entrada ended 2025 with approximately $296 million on its balance sheet, providing a cash runway into Q3 2027.
- Entrada's strategy for its Duchenne muscular dystrophy (DMD) programs involves running studies outside the U.S. to collect data, aiming for double-digit dystrophin production in the ENTR-601-44 program, and then pursuing accelerated approval in the U.S..
7 days ago
Entrada Therapeutics Highlights 2026 Catalysts and Financial Position at J.P. Morgan Healthcare Conference
TRDA
Product Launch
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates several value-driving catalysts in 2026, including top-line data from the first cohort of its ENTR-601-44 program in Q2 2026, first cohort data for ENTR-601-45 in mid-2026, and completion of enrollment and dosing for the VX-670 DM1 program with Vertex by mid-2026.
- The company ended 2025 with $296 million on its balance sheet, providing a cash runway into Q3 2027.
- Entrada has expanded its focus into ocular diseases, nominating ENTR-801 for Usher syndrome type 2A as its first clinical candidate in this area, with plans for a second candidate in 2026.
- The partnership with Vertex for the VX-670 DM1 program included $224 million upfront, a $26 million equity investment, and potential for $485 million in milestones.
7 days ago
Entrada Therapeutics Highlights Progress and Upcoming Milestones in 2026
TRDA
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates multiple clinical data readouts in 2026 for its Duchenne muscular dystrophy (DMD) programs, including top-line data for ENTR-601-44 in Q2 2026 and for ENTR-601-45 in mid-2026.
- The company's partnership with Vertex for the myotonic dystrophy type 1 (DM1) program, VX-670, expects completion of enrollment and dosing for the multiple ascending dose portion by mid-2026.
- Entrada announced an expansion into ocular diseases, nominating ENTR-801 for Usher syndrome type 2A, and plans to announce another clinical candidate in this area in 2026.
- Entrada ended 2025 with $296 million on its balance sheet, providing a cash runway into Q3 2027.
7 days ago
Entrada Therapeutics Provides Update on Clinical Programs and Financial Outlook
TRDA
Guidance Update
New Projects/Investments
- Entrada Therapeutics (TRDA) is a clinical-stage biotech company focused on developing therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), leveraging its proprietary Endosomal Escape Vehicle (EEV) technology platform.
- The company reported a cash position of $354 million, which is projected to provide an operational runway into Q2 2027.
- Key clinical data catalysts are anticipated in 2026: initial patient data for the DMD exon 44 program (ENTR-601-44) in H1 2026, and for the DMD exon 45 program (ENTR-601-45) in mid-2026.
- The DM1 program (VX-670), developed in partnership with Vertex Pharmaceuticals, is expected to complete dosing and enrollment of its multiple ascending dose (MAD) portion in 2026. Vertex initially paid $224 million for this preclinical asset.
- Entrada's EEV platform is highlighted for its ability to achieve high target engagement with low doses and low manufacturing costs, offering a flexible therapeutic approach that differentiates it from competing and current therapies, particularly in the DMD landscape where gene therapies have encountered challenges.
Sep 25, 2025, 2:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more